Loading...
Market
What percentage of TED patients will achieve complete resolution of diplopia with VRDN-001 by the end of 2025?
2
Viridian Therapeutics•Veligrotug•Clinical Activity Score•Viridian•Biologics License Application•Amgen
Resolution / Starting Odds
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Clinical trial results published by Viridian Therapeutics
Story
Viridian Therapeutics Announces Positive Results from Phase 3 THRIVE Trial for TED with VRDN-001 Veligrotug
Sep 10, 2024, 11:06 AM
Viridian Therapeutics announced positive topline results from its Phase 3 THRIVE clinical trial of Veligrotug (VRDN-001), an experimental treatment for thyroid eye disease (TED). The results showed significant improvement in reducing eye bulging and achieving primary goals. Key findings include a 70% proptosis responder rate, 54% complete resolution of diplopia, and 64% reduction of Clinical Activity Score to 0 or 1. The treatment was well-tolerated with no treatment-related serious adverse events. Viridian plans to submit a Biologics License Application (BLA) in 2025. The results compared favorably to a similar drug already approved and sold by Amgen. A webcast to discuss the results is scheduled for September 10, 2024, at 8:00am ET.
View original story
Similar markets
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
Less than 20% • 33%
20-40% • 33%
More than 40% • 33%
Less than 50% • 25%
50% to 70% • 25%
71% to 90% • 25%
More than 90% • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
0-5 patients • 25%
6-10 patients • 25%
11-15 patients • 25%
More than 15 patients • 25%
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
Less than 40% • 25%
40% to 60% • 25%
61% to 80% • 25%
More than 80% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Below 80% • 25%
80% to 85% • 25%
85% to 90% • 25%
Above 90% • 25%